Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1476-4598

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Combination strategies with PD-1/PD-L1 blockade: current advances and future directions ; volume:21 ; number:1 ; day:21 ; month:1 ; year:2022 ; pages:1-27 ; date:12.2022
Molecular cancer ; 21, Heft 1 (21.1.2022), 1-27, 12.2022

Creator: Yi, Ming
Zheng, Xiaoli
Niu, Mengke
Zhu, Shuangli
Ge, Hong
Wu, Kongming

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12943-021-01489-2

URN: urn:nbn:de:101:1-2022050219473580368898

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:36 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Yi, Ming
Zheng, Xiaoli
Niu, Mengke
Zhu, Shuangli
Ge, Hong
Wu, Kongming
SpringerLink (Online service)

Other Objects (12)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Regulatory mechanisms of PD-1/PD-L1 in cancers

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Regulatory mechanisms of PD-1/PD-L1 in cancers

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Regulatory mechanisms of PD-1/PD-L1 in cancers

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Regulatory mechanisms of PD-1/PD-L1 in cancers

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Regulatory mechanisms of PD-1/PD-L1 in cancers

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders

PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis

Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Regulatory mechanisms of PD-1/PD-L1 in cancers

Related objects

Reset password